Global Allogenic CAR-T Cell Therapy Market Report and Forecast 2024-2032

1    Preface
    1.1    Objectives of the Study
    1.2    Key Assumptions
    1.3    Report Coverage – Key Segmentation and Scope 
    1.4    Research Methodology
2    Executive Summary
3    Global Allogenic Car-T Cell Therapy Market Overview 
    3.1    Global Allogenic Car-T Cell Therapy Market Historical Value (2017-2023) 
    3.2    Global Allogenic Car-T Cell Therapy Market Forecast Value (2024-2032)
4    Vendor Positioning Analysis
    4.1    Key Vendors
    4.2    Prospective Leaders
    4.3    Niche Leaders
    4.4    Disruptors
5    Global Allogenic Car-T Cell Therapy Market Landscape*
    5.1    Global Allogenic Car-T Cell Therapy: Developers Landscape
        5.1.1    Analysis by Year of Establishment
        5.1.2    Analysis by Company Size
        5.1.3    Analysis by Region
    5.2    Global Allogenic Car-T Cell Therapy: Product Landscape 
        5.2.1    Analysis by Therapeutic Area
        5.2.2    Analysis by Source of Cell
6    Global Allogenic Car-T Cell Therapy Market Dynamics
    6.1    Market Drivers and Constraints
    6.2    SWOT Analysis
        6.2.1    Strengths
        6.2.2    Weaknesses
        6.2.3    Opportunities
        6.2.4    Threats
    6.3    PESTEL Analysis 
        6.3.1    Political 
        6.3.2    Economic 
        6.3.3    Social 
        6.3.4    Technological 
        6.3.5    Legal 
        6.3.6    Environment
    6.4    Porter’s Five Forces Model
        6.4.1    Bargaining Power of Suppliers
        6.4.2    Bargaining Power of Buyers
        6.4.3    Threat of New Entrants
        6.4.4    Threat of Substitutes
        6.4.5    Degree of Rivalry
    6.5    Key Demand Indicators 
    6.6    Key Price Indicators
    6.7    Industry Events, Initiatives, and Trends  
    6.8    Value Chain Analysis
7    Global  Allogenic Car-T Cell Therapy Market Segmentation (2017-2032)
    7.1    Global Allogenic Car-T Cell Therapy Market (2017-2032) by Therapeutic Area
        7.1.1    Market Overview
        7.1.2    Oncological Disorders
        7.1.3    Neurological Disorders
        7.1.4    Musculoskeletal Disorder
        7.1.5    Autoimmune / Inflammatory Disorders
        7.1.6    Post-Transplant Infections
        7.1.7    Others
    7.2    Global Allogenic Car-T Cell Therapy Market (2017-2032) by Indication
        7.2.1    Market Overview
        7.2.2    Bone Disorder
        7.2.3    Critical Limb Ischemia
        7.2.4    Crohn’s Disease
        7.2.5    Diabetic Foot Ulcer
        7.2.6    Graft versus Host Disease
        7.2.7    Leukemia
        7.2.8    Lymphoma
        7.2.9    Myelodysplastic Syndrome
        7.2.10    Cytomegalovirus Infection
        7.2.11    Others
    7.3    Global Allogenic Car-T Cell Therapy Market (2017-2032) by Source of Cell
        7.3.1    Market Overview
        7.3.2    Peripheral Blood
        7.3.3    Bone Marrow
        7.3.4    Umbilical Cord Blood
        7.3.5    Adipose Tissue
    7.4    Global Allogenic Car-T Cell Therapy Market (2017-2032) by Region
        7.4.1    Market Overview
        7.4.2    North America 
        7.4.3    Europe
        7.4.4    Asia Pacific
        7.4.5    Latin America
        7.4.6    Middle East and Africa
8    North America Allogenic Car-T Cell Therapy Market (2017-2032)
    8.1    North America Allogenic Car-T Cell Therapy Market (2017-2032) by Therapeutic Area
        8.1.1    Market Overview
        8.1.2    Oncological Disorders
        8.1.3    Neurological Disorders
        8.1.4    Musculoskeletal Disorder
        8.1.5    Autoimmune / Inflammatory Disorders
        8.1.6    Post-Transplant Infections
        8.1.7    Others
    8.2    North America Allogenic Car-T Cell Therapy Market (2017-2032) by Indication
        8.2.1    Market Overview
        8.2.2    Bone Disorder
        8.2.3    Critical Limb Ischemia
        8.2.4    Crohn’s Disease
        8.2.5    Diabetic Foot Ulcer
        8.2.6    Graft versus Host Disease
        8.2.7    Leukemia
        8.2.8    Lymphoma
        8.2.9    Myelodysplastic Syndrome
        8.2.10    Cytomegalovirus Infection
        8.2.11    Others
    8.3    North America Allogenic Car-T Cell Therapy Market (2017-2032) by Source of Cell
        8.3.1    Market Overview
        8.3.2    Peripheral Blood
        8.3.3    Bone Marrow
        8.3.4    Umbilical Cord Blood
        8.3.5    Adipose Tissue
        8.3.6    Adipose Tissue
    8.4    North America Allogenic Car-T Cell Therapy Market (2017-2032) by Country
        8.4.1    United States of America
        8.4.2    Canada
9    Europe Allogenic Car-T Cell Therapy Market (2017-2032)
    9.1    Europe Allogenic Car-T Cell Therapy Market (2017-2032) by Therapeutic Area
        9.1.1    Market Overview
        9.1.2    Oncological Disorders
        9.1.3    Neurological Disorders
        9.1.4    Musculoskeletal Disorder
        9.1.5    Autoimmune / Inflammatory Disorders
        9.1.6    Post-Transplant Infections
        9.1.7    Others
    9.2    Europe Allogenic Car-T Cell Therapy Market (2017-2032) by Indication
        9.2.1    Market Overview
        9.2.2    Bone Disorder
        9.2.3    Critical Limb Ischemia
        9.2.4    Crohn’s Disease
        9.2.5    Diabetic Foot Ulcer
        9.2.6    Graft versus Host Disease
        9.2.7    Leukemia
        9.2.8    Lymphoma
        9.2.9    Myelodysplastic Syndrome
        9.2.10    Cytomegalovirus Infection
        9.2.11    Others
    9.3    Europe Allogenic Car-T Cell Therapy Market (2017-2032) by Source of Cell
        9.3.1    Market Overview
        9.3.2    Peripheral Blood
        9.3.3    Bone Marrow
        9.3.4    Umbilical Cord Blood
        9.3.5    Adipose Tissue
        9.3.6    Adipose Tissue
    9.4    Europe Allogenic Car-T Cell Therapy Market (2017-2032) by Country
        9.4.1    United Kingdom
        9.4.2    Germany
        9.4.3    France
        9.4.4    Italy
        9.4.5    Others
10    Asia Pacific Allogenic Car-T Cell Therapy Market (2017-2032)
    10.1    Asia Pacific Allogenic Car-T Cell Therapy Market (2017-2032) by Therapeutic Area
        10.1.1    Market Overview
        10.1.2    Oncological Disorders
        10.1.3    Neurological Disorders
        10.1.4    Musculoskeletal Disorder
        10.1.5    Autoimmune / Inflammatory Disorders
        10.1.6    Post-Transplant Infections
        10.1.7    Others
    10.2    Asia Pacific Allogenic Car-T Cell Therapy Market (2017-2032) by Indication
        10.2.1    Market Overview
        10.2.2    Bone Disorder
        10.2.3    Critical Limb Ischemia
        10.2.4    Crohn’s Disease
        10.2.5    Diabetic Foot Ulcer
        10.2.6    Graft versus Host Disease
        10.2.7    Leukemia
        10.2.8    Lymphoma
        10.2.9    Myelodysplastic Syndrome
        10.2.10    Cytomegalovirus Infection
        10.2.11    Others
    10.3    Asia Pacific Allogenic Car-T Cell Therapy Market (2017-2032) by Source of Cell
        10.3.1    Market Overview
        10.3.2    Peripheral Blood
        10.3.3    Bone Marrow
        10.3.4    Umbilical Cord Blood
        10.3.5    Adipose Tissue
        10.3.6    Adipose Tissue
    10.4    Asia Pacific Allogenic Car-T Cell Therapy Market (2017-2032) by Country
        10.4.1    China
        10.4.2    Japan
        10.4.3    India
        10.4.4    ASEAN
        10.4.5    Australia
        10.4.6    Others
11    Latin America Allogenic  Car-T Cell Therapy Market (2017-2032)
    11.1    Latin America Allogenic Car-T Cell Therapy Market (2017-2032) by Therapeutic Area
        11.1.1    Market Overview
        11.1.2    Oncological Disorders
        11.1.3    Neurological Disorders
        11.1.4    Musculoskeletal Disorder
        11.1.5    Autoimmune / Inflammatory Disorders
        11.1.6    Post-Transplant Infections
        11.1.7    Others
    11.2    Latin America Allogenic Car-T Cell Therapy Market (2017-2032) by Indication
        11.2.1    Market Overview
        11.2.2    Bone Disorder
        11.2.3    Critical Limb Ischemia
        11.2.4    Crohn’s Disease
        11.2.5    Diabetic Foot Ulcer
        11.2.6    Graft versus Host Disease
        11.2.7    Leukemia
        11.2.8    Lymphoma
        11.2.9    Myelodysplastic Syndrome
        11.2.10    Cytomegalovirus Infection
        11.2.11    Others
    11.3    Latin America Allogenic Car-T Cell Therapy Market (2017-2032) by Source of Cell
        11.3.1    Market Overview
        11.3.2    Peripheral Blood
        11.3.3    Bone Marrow
        11.3.4    Umbilical Cord Blood
        11.3.5    Adipose Tissue
        11.3.6    Adipose Tissue
    11.4    Latin America Allogenic Car-T Cell Therapy Market (2017-2032) by Country
        11.4.1    Brazil
        11.4.2    Argentina
        11.4.3    Mexico
        11.4.4    Others
12    Middle East and Africa Allogenic Car-T Cell Therapy Market (2017-2032)
    12.1    Middle East and Africa Allogenic Car-T Cell Therapy Market (2017-2032) by Therapeutic Area
        12.1.1    Market Overview
        12.1.2    Oncological Disorders
        12.1.3    Neurological Disorders
        12.1.4    Musculoskeletal Disorder
        12.1.5    Autoimmune / Inflammatory Disorders
        12.1.6    Post-Transplant Infections
        12.1.7    Others
    12.2    Middle East and Africa Allogenic Car-T Cell Therapy Market (2017-2032) by Indication
        12.2.1    Market Overview
        12.2.2    Bone Disorder
        12.2.3    Critical Limb Ischemia
        12.2.4    Crohn’s Disease
        12.2.5    Diabetic Foot Ulcer
        12.2.6    Graft versus Host Disease
        12.2.7    Leukemia
        12.2.8    Lymphoma
        12.2.9    Myelodysplastic Syndrome
        12.2.10    Cytomegalovirus Infection
        12.2.11    Others
    12.3    Middle East and Africa Allogenic Car-T Cell Therapy Market (2017-2032) by Source of Cell
        12.3.1    Market Overview
        12.3.2    Peripheral Blood
        12.3.3    Bone Marrow
        12.3.4    Umbilical Cord Blood
        12.3.5    Adipose Tissue
        12.3.6    Adipose Tissue
    12.4    Middle East and Africa Allogenic Car-T Cell Therapy Market (2017-2032) by Country
        12.4.1    Saudi Arabia
        12.4.2    United Arab Emirates
        12.4.3    Nigeria
        12.4.4    South Africa
        12.4.5    Others
13    Regulatory  Framework
    13.1    Regulatory Overview
    13.2    US FDA
    13.3    EU EMA
    13.4    INDIA CDSCO
    13.5    JAPAN PMDA
    13.6    Others
14    Patent Analysis
    14.1     Analysis by Type of Patent
    14.2     Analysis by Publication Year
    14.3     Analysis by Issuing Authority
    14.4     Analysis by Patent Age
    14.5     Analysis by CPC Analysis
    14.6     Analysis by Patent Valuation 
    14.7     Analysis by Key Players
15    Clinical Trial Analysis
    15.1    Analysis by Trial Registration Year
    15.2    Analysis by Trial Status
    15.3    Analysis by Trial Phase
    15.4    Analysis by Therapeutic Area
    15.5    Analysis by Geography
16    Grant Analysis
    16.1    Analysis by Year
    16.2    Analysis by Amount Awarded
    16.3    Analysis by Issuing Authority
    16.4    Analysis by Grant Product
    16.5    Analysis by Funding Institute
    16.6    Analysis by Departments
    16.7    Analysis by Recipient Organization
17    Funding and Investment Analysis
    17.1     Analysis by Funding Instances
    17.2     Analysis by Type of Funding
    17.3     Analysis by Funding Amount
    17.4     Analysis by Leading Players
    17.5     Analysis by Leading Investors
    17.6     Analysis by Geography
18    Strategic Initiatives
    18.1     Analysis by Partnership Instances
    18.2     Analysis by Type of Partnership
    18.3     Analysis by Leading Players
    18.4     Analysis by Geography
19    Supplier Landscape
    19.1    Market Share Analysis, By Region (Top 5 Companies)
        19.1.1    Market Share Analysis: Global
        19.1.2    Market Share Analysis: North America
        19.1.3    Market Share Analysis: Europe
        19.1.4    Market Share Analysis: Asia Pacific
        19.1.5    Market Share Analysis: Others
    19.2    Artiva Biotherapeutics, Inc.
        19.2.1    Financial Analysis
        19.2.2    Product Portfolio
        19.2.3    Demographic Reach and Achievements
        19.2.4    Mergers and Acquisitions
        19.2.5    Certifications 
    19.3    Allogene Therapeutics Inc.
        19.3.1    Financial Analysis
        19.3.2    Product Portfolio
        19.3.3    Demographic Reach and Achievements
        19.3.4    Mergers and Acquisitions
        19.3.5    Certifications
    19.4    Atara Biotherapeutics Inc.
        19.4.1    Financial Analysis
        19.4.2    Product Portfolio
        19.4.3    Demographic Reach and Achievements
        19.4.4    Mergers and Acquisitions
        19.4.5    Certifications
    19.5    Cellenkos Inc.
        19.5.1    Financial Analysis
        19.5.2    Product Portfolio
        19.5.3    Demographic Reach and Achievements
        19.5.4    Mergers and Acquisitions
        19.5.5    Certifications
    19.6    Cell2Cure Aps 
        19.6.1    Financial Analysis
        19.6.2    Product Portfolio
        19.6.3    Demographic Reach and Achievements
        19.6.4    Mergers and Acquisitions
        19.6.5    Certifications
    19.7    Celularity, Inc.
        19.7.1    Financial Analysis
        19.7.2    Product Portfolio
        19.7.3    Demographic Reach and Achievements
        19.7.4    Mergers and Acquisitions
        19.7.5    Certifications
    19.8    Cellular Biomedicine Group, Inc.
        19.8.1    Financial Analysis
        19.8.2    Product Portfolio
        19.8.3    Demographic Reach and Achievements
        19.8.4    Mergers and Acquisitions
        19.8.5    Certifications
    19.9    Chabiotech Co., Ltd.
        19.9.1    Financial Analysis
        19.9.2    Product Portfolio
        19.9.3    Demographic Reach and Achievements
        19.9.4    Mergers and Acquisitionsl
        19.9.5    Certifications 
    19.10    CRISPR Therapeutics AG 
        19.10.1    Financial Analysis
        19.10.2    Product Portfolio
        19.10.3    Demographic Reach and Achievements
        19.10.4    Mergers and Acquisitions
        19.10.5    Certifications 
20    Allogenic Car-T Cell Therapy Market – Distribution Model (Additional Insight)
    20.1     Overview 
    20.2     Potential Distributors 
    20.3     Key Parameters for Distribution Partner Assessment 
21    Key Opinion Leaders (KOL) Insights (Additional Insight)

*Additional insights provided are customisable as per client requirements.

* The coverage of the Market Landscape section depends on the data availability and may cover a minimum of 80% of the total market. The EMR team strives to make this section as comprehensive as possible.

**The supplier list is not exhaustive. Moreover, we can provide analysis of companies as per custom requests.